SCHEMBL1944359

SCHEMBL1944359

c1cc(CNc2nn3cc(-c4ccsc4)nc3s2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 7/20 0.50
CYP17A1 P05093 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
TP53 P04637 7/20 0.39
MAPT P10636 4/20 0.39
ROCK2 O75116 2/20 0.38
ROCK1 Q13464 2/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
LYN P07948 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
AKT1 P31749 1/20 0.38
FLT3 P36888 1/20 0.38
CSNK1D P48730 1/20 0.38
CLK2 P49760 1/20 0.38
IRAK1 P51617 1/20 0.38
PRKX P51817 1/20 0.38
NEK4 P51957 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946536 0.90 TP53 (0.47) FYNTP53MAPTROCK2ROCK1
SCHEMBL1944600 0.89 FYN (0.52) FYNCYP17A1CYP11B1CYP11B2TP53
SCHEMBL1944669 0.88 F2RL3 (0.46) FYNTP53MAPTSMN1; SMN2
SCHEMBL1946641 0.87 FYN (0.48) FYNTP53ROCK2ROCK1SMN1; SMN2
SCHEMBL1945080 0.85 F2RL3 (0.52) FYNTP53MAPT
SCHEMBL1947227 0.85 RAB9A (0.45) FYNTP53MAPTSMN1; SMN2NPC1
SCHEMBL1944422 0.85 TP53 (0.52) FYNTP53MAPTROCK2ROCK1
SCHEMBL1945445 0.85 TP53 (0.56) FYNTP53MAPTROCK2ROCK1
SCHEMBL1945139 0.83 FYN (0.50) FYNTP53MAPTSMN1; SMN2NPC1
SCHEMBL2257205 0.83 F2RL3 (0.50) FYNTP53MAPTROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R FYN 1977/4885CYP17A1 1749/4885CYP11B1 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.